Student or educator? Sign up with your school email and get 6 months of Pro free.
CoChat

The DOI matches its Crossref record; 105 of the 107 references it cites were found in a registry or an index.

Challenges of the pharmacological management of benzodiazepine withdrawal, dependence, and discontinuation

Open access
Fluyau, Dimy, Revadigar, Neelambika, Manobianco, Brittany E. · 2018 · Therapeutic Advances in Psychopharmacology

Abstract

BACKGROUND: Benzodiazepines (BZDs) are among the most prescribed sedative hypnotics and among the most misused and abused medications by patients, in parallel with opioids. It is estimated that more than 100 million Benzodiazepine (BZD) prescriptions were written in the United States in 2009. While medically useful, BZDs are potentially dangerous. The co-occurring abuse of opioids and BZD, as well as increases in BZD abuse, tolerance, dependence, and short- and long-term side effects, have prompted a worldwide discussion about the challenging aspects of medically managing the discontinuation of BZDs. Abrupt cessation can cause death. This paper addresses the challenges of medications suggested for the management of BZD discontinuation, their efficacy, the risks of abuse and associated medical complications. The focus of this review is on the challenges of several medications suggested for the management of BZD discontinuation, their efficacy, the risks of abuse, and associated medical complications. METHODS: An electronic search was performed of Medline, Worldwide Science, Directory of Open Access Journals, Embase, Cochrane Library, Google Scholar, PubMed Central, and PubMed from 1990 to 2017. The review includes double-blind, placebo-controlled studies for the most part, open-label pilot studies, and animal studies, in addition to observational research. We expand the search to review articles, naturalistic studies, and to a lesser extent, letters to the editor/case reports. We exclude abstract and poster presentations, books, and book chapters. RESULTS: The efficacy of these medications is not robust. While some of these medicines are relatively safe to use, some of them have a narrow therapeutic index, with severe, life-threatening side effects. Randomized studies have been limited. There is a paucity of comparative research. The review has several limitations. The quality of the documents varies according to whether they are randomized studies, nonrandomized studies, naturalistic studies, pilot studies, letters to the editors, or case reports. CONCLUSIONS: The use of medications for the discontinuation of BZDs seems appropriate. It is a challenge that requires further investigation through randomized clinical trials to maximize efficacy and to minimize additional risks and side effects.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1177/2045125317753340

Cites

105 of 105 references verified0 citation errors · 0 not checkable

Statistics

Figures

Figure 1. Benzodiazepine binds to γ-aminobutyric acid (GABA) receptor (blue) to open chloride channel (purple). Alcohol (green) cross reacts with the same receptor. The result is the modulation of GABA producing an anxiolytic effect. Adapted from the work of: BruceBlaus. Cell GABA Receptor. November 12 2015. https://commons.wikimedia.org/wiki/File:Cell_GABA_Receptor.png. This file is licensed under the Creative Commons Attribution-Share Alike 4.0 International license. No permission is required.
Figure 1. Benzodiazepine binds to γ-aminobutyric acid (GABA) receptor (blue) to open chloride channel (purple). Alcohol (green) cross reacts with the same receptor. The result is the modulation of GABA producing an anxiolytic effect. Adapted from the work of: BruceBlaus. Cell GABA Receptor. November 12 2015. https://commons.wikimedia.org/wiki/File:Cell_GABA_Receptor.png. This file is licensed under the Creative Commons Attribution-Share Alike 4.0 International license. No permission is required.CC BY-NC · PubMed Central
Figure 2. The number of deaths from benzodiazepines is trending up (from 2002 to 2015). Note that the number is higher for men than for women. Adapted from the work of the National Institutes of Health, part of the United States Department of Health and Human Services. “National Overdose Deaths—Number of Deaths from Benzodiazepines, with and without opioids. Source 2002–2015 chart from Overdose Death Rates. By National Institute on Drug Abuse (NIDA).
Figure 2. The number of deaths from benzodiazepines is trending up (from 2002 to 2015). Note that the number is higher for men than for women. Adapted from the work of the National Institutes of Health, part of the United States Department of Health and Human Services. “National Overdose Deaths—Number of Deaths from Benzodiazepines, with and without opioids. Source 2002–2015 chart from Overdose Death Rates. By National Institute on Drug Abuse (NIDA).CC BY-NC · PubMed Central
Figure 3. Number of times a drug appeared at a level of evidence. Carbamazepine, flumazenil, propranolol, and melatonin seem to be the most studied. The highest number of studies for carbamazepine is at level III, but the highest number of studies for melatonin is at level I; 67% of the drugs fall at least in one randomized controlled trial (level I). Grey: level I; yellow: level II-1; light blue: level II-2; green: level II-3; dark blue: level III.
Figure 3. Number of times a drug appeared at a level of evidence. Carbamazepine, flumazenil, propranolol, and melatonin seem to be the most studied. The highest number of studies for carbamazepine is at level III, but the highest number of studies for melatonin is at level I; 67% of the drugs fall at least in one randomized controlled trial (level I). Grey: level I; yellow: level II-1; light blue: level II-2; green: level II-3; dark blue: level III.CC BY-NC · PubMed Central

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

1 retracted

Show all 107 references

Research works printed but not linked: 23

  1. Pal R, 2015, The ASAM essential of addiction medicine, 53
  2. SAMSHA, 2012, The DAWN report: highlights of the 2010 Drug Abuse Warning Network finding in drug-related emergency department visits
  3. Jones CM, 2014, MMWR Morb Mortal Wkly Rep, 63, 881
  4. Griffin CE, 2013, Ochsner J, 13, 214
  5. Sieghart W., 1994, J Psychiatry Neurosci, 19, 24
  6. Meibach RC, 1987, J Clin Psychiatry, 48, 355
  7. King TL, Brucker MC. Pharmacology for women’s health. 2nd ed. Sudbury: Jones & Bartlett Publishers, 2010, pp.372–373.
  8. Ng F, 2007, Neuropsychiatr Dis Treat, 3, 463
  9. Birkhimer LJ, 1985, Clin Pharm, 4, 425
  10. Kasson BJ., 1992, J Am Assoc Nurse Anesth, 60, 464
  11. Griffin CE, 2013, Ochsner J, 13, 214
  12. Comai S, 2013, Brain Res, 243, 231
  13. Faccini M, 2012, Risk Manag Healthc Policy, 5, 43
  14. Olsen RW, DeLorey TM. GABA receptor physiology and pharmacology. Basic neurochemistry: molecular, cellular and medical aspects. Lippincott-Raven, https://www.ncbi.nlm.nih.gov/books/NBK28090 (1999, accessed May 2017).
  15. Kumar AA, 2014, Int J Pharm Bio Sci, 5, 1
  16. 10.18773/austprescr.2015.055 · DOI · Paper page
  17. James J., 2016, Aust Prescr, 39, 96
  18. 10.1001/jama.1987.03390040137034 · doi:10.1001/jama.1987.03390040137034
  19. Patterson JF, 1990, J Clin Psychiatry, 51, 47
  20. Hantouche EG, 1998, Encephale, 24, 469
  21. Chandrasekaran PK., 2008, Singapore Med J, 49, 166
  22. 10.1007/BF02246214 · DOI
  23. 10.1007/s00228-001-0387-4 · DOI · Paper page

Cited by

See all 109

Metadata

Authors
Fluyau, D., Revadigar, N., & Manobianco, B. E.
Affiliations
  • Emory University (US)
  • Columbia University (US)
Corresponding author
Fluyau, Dimy
Venue
Therapeutic Advances in Psychopharmacology
Published
2018-02-09
Volume
8
Issue
5
Pages
147-168
ISSN
  • 2045-1253 (ISSN-L)
  • 2045-1261
OpenAlex
W2793118967
Cited by
109
References
107
Citations by year
2026: 9 · 2025: 16 · 2024: 8 · 2023: 15 · 2022: 19 · 2021: 18 · 2020: 14 · 2019: 8 · 2018: 1
FWCI
1.46
Type
journal article
Language
en
Open access
Licence
  • cc-by-nc
  • journals.sagepub.com/page/policies/text-and-data-mining-license (tdm)
Locations
  • Therapeutic Advances in Psychopharmacology (publishedVersion, cc-by-nc)
  • Europe PMC (PubMed Central) (publishedVersion, cc-by-nc)
  • PubMed Central (publishedVersion, cc-by-nc)
  • PubMed (publishedVersion)
Topics
  • Health Sciences › Medicine › Epidemiology › Substance Abuse Treatment and Outcomes
  • Health Sciences › Medicine › Geriatrics and Gerontology › Pharmaceutical Practices and Patient Outcomes
  • Health Sciences › Medicine › Public Health, Environmental and Occupational Health › Opioid Use Disorder Treatment
Keywords
benzodiazepines, benzodiazepine withdrawal, benzodiazepine dependence, benzodiazepine discontinuation, pharmacological management, benzodiazepine misuse, drug tolerance, adverse effects, narrow therapeutic index

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Challenges of the pharmacological management of benzodiazepine withdrawal, dependence, and discontinuation. https://app.cochat.ai/papers/10.1177/2045125317753340
The paper
Fluyau, D., Revadigar, N., & Manobianco, B. E. (2018). Challenges of the pharmacological management of benzodiazepine withdrawal, dependence, and discontinuation. Therapeutic Advances in Psychopharmacology. https://doi.org/10.1177/2045125317753340

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.